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Abstract  
The impact of HIV infection on innate and adaptive immune activation occurs in the context of host 
factors which serve to augment or dampen the physiologic response to the virus. Nutritional status, and 
in particular body composition, affects innate immune activation through a range of conditions including 
the loss of mucosal barrier protections and microbiome dysbiosis in malnutrition to the pro-
inflammatory contribution of adipocytes and stromal vascular cells in obesity. Similarly, T cell activation, 
proliferation, and cytokine expression are reduced in the setting of malnutrition and increased in 
obesity, potentially due to adipokine regulatory mechanisms restraining energy-avid adaptive immunity 
in times of starvation and exerting a paradoxical effect in overnutrition. The response to HIV infection is 
situated within these complex interactions between host nutritional health and immunologic function, 
which contribute to the varied phenotypes of immune activation among HIV patients across a spectrum 
from malnutrition to obesity. 
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Introduction 1 
Following the introduction of effective antiretroviral therapy (ART) in resource-rich, developed 2 
countries, the incidence of HIV-associated wasting in advanced disease has declined while the 3 
proportion of overweight and obese HIV-infected individuals on long-term treatment has steadily risen 4 
[1, 2]. In contrast, due to the geographic overlap of high HIV prevalence and chronic food insecurity, 5 
new infections frequently occur against a backdrop of chronically insufficient macronutrient intake 6 
(hereafter referred to as malnutrition) [3]. Host nutritional status affects innate immune activation 7 
through a variety of mechanisms from altered mucosal barrier defenses and microbiome in malnutrition 8 
to pro-inflammatory cytokine expression by stromal vascular cells and hypertrophied adipocytes in 9 
obesity. Similarly, nutritional status modulates T cell activation, proliferation, and function, in part via 10 
endocrine mechanisms thought to act on T cell surface receptors. Here, we review the interaction of 11 
nutrition and the immune response to HIV across the spectrum of nutritional status ranging from 12 
malnutrition to obesity (summarized in the Figure). 13 
 14 
Part 1: HIV and Malnutrition in Resource-Rich and Resource-Limited Contexts 15 
The young, emaciated patient with advanced AIDS is an enduring image of the early HIV epidemic, and 16 
can unfortunately still be found with alarming frequency in many resource-limited settings where HIV 17 
testing and treatment have not become universally available or accepted. However, a low body mass 18 
index (BMI, a marker of generalized malnutrition) in the setting of HIV infection should be divided into 19 
two frequently overlapping phenotypes. The first, cachexia, is a wasting phenotype characterized by a 20 
dangerous cycle involving profound loss of adaptive immune system protection (i.e., CD4+ T cell 21 
depletion), increased basal metabolic rate (due in part to a persistent inflammatory response), and 22 
increased protein catabolism with accelerates the loss of lean body mass [4-10]. The second phenotype 23 
arises from the simultaneous presence of clinical malnutrition due to insufficient caloric intake and 24 
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concomitant HIV infection in varying stages of immunosuppression. Global surveys estimate that over 25 
800 million individuals have chronically insufficient caloric intake, with the highest prevalence in sub-26 
Saharan Africa and Southern Asia [11]. The prevalence of low BMI can be substantial in African HIV 27 
patient populations; in a study of HIV-infected adults at clinics across Lusaka, the capitol of Zambia, one-28 
third were malnourished (BMI <18.5 kg/m2) at the time of ART initiation [12]. Frequently these 29 
phenotypes overlap. In resource-rich settings progressive weight loss with untreated HIV leads to low 30 
BMI and its associated organ system dysfunction and immune deficits, while in resource-limited settings 31 
the immune deficits accompanying a low BMI are exacerbated by the acquisition of HIV infection. 32 
 33 
Malnutrition, enteropathy and microbial translocation 34 
The combined effects of environmental factors, nutrient deficits, and HIV infection on gastrointestinal 35 
mucosal barrier defenses and microbiome composition (discussed below) contribute to increased 36 
translocation of microbes and microbial proteins into the bowel wall and circulation in malnourished, 37 
HIV-infected individuals [13-16]. Microbial translocation, as measured by circulating lipopolysaccharide 38 
(LPS; a component of the bacterial cell wall), anti-endotoxin IgM and IgG antibodies, soluble CD14, and 39 
other biomarkers is associated with accelerated HIV disease progression and a higher risk of mortality in 40 
untreated HIV infection [17, 18], though the prognostic value of these biomarkers is less clear after ART 41 
initiation [19, 20]. The loss of barrier defenses against microbial translocation in HIV infection also has 42 
consequences for adaptive immune activation. In Italian HIV patients, serum LPS levels predicted disease 43 
progression independently of age, CD4+ T-cell count, viral load, or duration of infection, and higher 44 
circulating LPS levels after ART initiation were associated with greater CD4+ and CD8+ T cell activation 45 
and poor CD4+ T cell recovery [17, 21]. 46 
 47 
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Malnutrition enteropathy is characterized by bowel wall edema, reduced nutrient absorption and bowel 48 
transit time, reduced secretory IgA production, and changes in mucosal surface morphology resulting in 49 
villous blunting, increased permeability, and local inflammation [22, 23]. Environmental enteropathy, 50 
thought to result from a combination of recurrent, transient infections with pathogenic bacteria and 51 
altered intestinal microbiota, is common in tropical regions with poor sanitation and is also 52 
characterized by villous blunting, reduced nutrient absorption, and accelerated bowel transit [16, 24-53 
26]. Lastly, HIV enteropathy is characterized by mucosal T cell depletion in conjunction with impaired 54 
cellular tight junctions between epithelial cells [27-29]. The ensuing inflammatory response produces 55 
villous changes similar to malnutrition enteropathy, which reduces nutrient absorption [30, 31]. In 56 
resource-limited settings, the gastrointestinal system of malnourished HIV-infected individuals can be 57 
affected by all three conditions simultaneously, and treatment of one condition (e.g., with ART 58 
initiation) may not reduce inflammation and microbial translocation due to concomitant conditions. 59 
 60 
Impaired gastrointestinal mucosal integrity and microbial translocation do not appear to be present 61 
during acute HIV infection, and the temporal course of systemic inflammation attributed to microbial 62 
translocation does not correspond entirely with markers of mucosal integrity or damage [15, 32]. 63 
Despite the initiation of ART and plasma viral suppression, defects in junctional complex expression, the 64 
presence of bacterial products in the lamina propria, and reduced IL-17 and IL-22 producing cells persist 65 
in treated HIV infection [28, 33], and even the early initiation of ART shortly after infection does not fully 66 
normalize gastrointestinal mucosal dysfunction markers [34]. These findings suggest the changes in 67 
mucosal integrity accompanying HIV infection involve permanent changes in gastrointestinal cellular 68 
function, including the loss of IL-17 and IL-22 producing cells and altered epithelial gene expression, 69 
which require time to emerge. While most studies of microbial translocation and innate immune 70 
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activation in HIV infection are from developed countries, similar findings are reported from resource-71 
limited settings [13, 14].  72 
 73 
Malnutrition, HIV, and the microbiome 74 
The centrality of the human gastrointestinal microbiome to the maintenance of host energy 75 
homeostasis and metabolism was recognized decades ago, but more recent evidence points to an 76 
important role modulating mucosal and systemic immune activity [35-37]. The human microbiome is 77 
composed of an estimated 1014 microbes, comprising approximately 1000 species that include archaea, 78 
bacteria and eukaryotes, but predominantly constituted by the five bacterial phyla of Firmicutes, 79 
Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia [38]. Quantitation of the relative 80 
proportions of each phyla, and more specific taxonomic ranks, have identified consistent phenotypes 81 
present in the setting of HIV infection, malnutrition, and states of persistent systemic inflammation and 82 
adaptive immune activation.  83 
 84 
An altered gastrointestinal microbiome appears to occur early in the course of HIV-infection and may 85 
contribute to, or is at least correlated with, mucosal inflammatory activity, mucosal CD4+ T cell 86 
depletion, and peripheral CD8+ T cell activation [39-41]. The microbiome alterations, and the 87 
accompanying local and systemic immune effects, persist following the early stages of infection and do 88 
not revert with ART treatment, possibly due to a persistent presence of HIV virus at the mucosal surface 89 
or the lasting depletion of gastrointestinal CD4+ T cells and other immune effectors despite effective 90 
suppression of plasma viremia [42, 43].  91 
 92 
In a study of rectosigmoid biopsies from HIV-infected subjects not yet on ART, ART-treated subjects, and 93 
HIV-negative controls, those with untreated HIV were found to have a marked dysbiosis of mucosal-94 
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adherent bacteria characterized by increased Proteobacteria and reduced Bacteroidetes, which was 95 
accompanied by increased mucosal CD4+ and CD8+ T cell activation, increased circulating CD8+ T cell 96 
activation, and, among ART-treated participants, increased circulating IL-6 [44]. In particular, the 97 
mucosal community was enriched for Proteobacteria genera including Salmonella, Escherichia, Serratia, 98 
Shigella, and Klebsiella species, all of which can act as pro-inflammatory pathobionts. A similar shift in 99 
gastrointestinal microbiome was seen in a subsequent study of colon biopsies of untreated HIV-infected 100 
persons, which found increased Proteobacteria, reduced Firmicutes, and alterations in the relative 101 
composition of the Bacteroidetes phyum compared to HIV-negative controls. Furthermore, the HIV-102 
associated changes in Bacteroidetes members, primarily an increase in Prevotella, were associated with 103 
both mucosal and circulating CD4+ and CD8+ T cell activation [45]. Similar associations between 104 
microbiome composition and systemic immune activation were observed in the fecal microbiome, 105 
including a potentially a potentially beneficial effect of fecal Lactobacillales (phylum Firmicutes) to 106 
promote circulating CD4+ T cell recovery and lower CD8+ T cell activation on ART [46, 47]. 107 
 108 
The preponderance of studies of HIV-negative, malnutrition-associated microbiome alterations enrolled 109 
children rather than adults, but despite this limitation the observed commonalities with HIV-associated 110 
gastrointestinal dysbiosis bear consideration. A link between kwashiorkor and a predominance of 111 
Staphylococcus aureus and coliform bacteria of the phylum Proteobacteria in gastric juice and rectal 112 
swabs was identified as early as 1958 [48]. Later studies of malnourished children and well-nourished 113 
controls in Bangladesh found poor nutritional status was associated with enrichment of Proteobacteria, 114 
including a 174-fold and nine-fold increase in Klebsiella and Escherichia respectively, and depletion of 115 
Bacteroidetes [49]. In Indian children, nutritional status was negatively correlated with the proportion of 116 
Proteobacteria (including Escherichia, Shigella, and Enterobacter) and positively correlated with the 117 
proportion of anaerobic Firmicutes (including Roseburia, Faecalibacterium, and Butyrivibrio) [50]. This 118 
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pattern of enriched Proteobacteria and depleted Bacteroidetes and Firmicutes accompanying 119 
malnutrition has also been observed in other case-control pediatric studies [51, 52]. 120 
 121 
At the phylum level, malnutrition is accompanied by gastrointestinal microbiome alterations similar to 122 
those observed in untreated and ART-treated HIV-infected persons. While additional studies are needed 123 
to confirm the dysbiosis observed in underweight children is also present in malnourished adults, it 124 
seems reasonable to assume that adult malnutrition is accompanied by some degree of enrichment of 125 
Proteobacteria and a depletion of Bacteroidetes and Firmicutes. To explore this further, we propose two 126 
areas as research priorities: first, to investigate commonalities in mucosal immune dysfunction leading 127 
to similar dysbiosis phenotypes in HIV infection and malnutrition; second, to determine the extent to 128 
which a high degree of persistent immune activation in malnourished, HIV-infected individuals can be 129 
attributed to compounding or synergistic effects of HIV and nutritional factors on the gastrointestinal 130 
microbiome.  131 
 132 
Food insecurity 133 
Food insecurity, or a lack of consistent access to a sufficient quantity of affordable, nutritious food, is 134 
associated with a higher likelihood of viral non-suppression in HIV-infected persons, with resultant 135 
effects on disease progression and immune activation [53, 54]. In the United States and Europe, food 136 
insecurity is more common among HIV patients with substance abuse, mental illness, and those living in 137 
poverty, while in resource-limited settings food insecurity is often endemic in areas with high HIV 138 
prevalence [55-57]. Food insecurity, and the frequently attendant economic privations, have adverse 139 
effects on clinic attendance, obtaining medication refills, and taking ART at the frequency and dosages 140 
prescribed, all of which lead to loss of virologic suppression, increased inflammation and cellular 141 
immune activation, and higher likelihood of ART regimen failure and resistance [58-60]. Food assistance 142 
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may have a role in incentivizing patients to attend clinic visits and collect medications as scheduled [57, 143 
61, 62]. 144 
 145 
A second aspect of food insecurity and immune activation is dietary quality, particularly in resource-146 
limited settings where HIV-infected individuals may be reliant on carbohydrate-rich staple foods (e.g., 147 
ground maize) with a high glycemic index. A recent systematic review of glycemic index and glycemic 148 
load dietary intervention studies suggests high carbohydrate staple foods increase IL-6, CRP, and other 149 
inflammation biomarkers [63], which may present an opportunity for properly-constituted food 150 
assistance to reduce chronic immune activation in addition to improving clinic attendance and ART 151 
adherence.  152 
 153 
Malnutrition and T cell function  154 
While there is a paucity of data from HIV-infected individuals, malnutrition is associated with broad 155 
suppression of antigen-specific immunity, including reduced T cell output, maturation, proliferation, and 156 
cytokine expression. The preponderance of these studies, by far, are in children or adolescents <18 157 
years old and are summarized in a recent systematic review [64]; the findings should be extrapolated to 158 
adults with some caution. Compared to the well-nourished, malnutrition is associated with reduced T 159 
cell proliferative responses, reduced T cell expression of activation and memory surface markers [65, 160 
66], and greater TH2 polarization with concomitant decreased TH1 cell IFN-γ and IL-2 production [66, 67]. 161 
Malnutrition is also accompanied by a lower likelihood of skin test conversion after Bacillus Calmette–162 
Guérin vaccination and reduced dermal delayed type hypersensitivity responses to Candida, 163 
phytohemagglutinin and other common recall antigens [68]. Lastly, while total IgG and other antibody 164 
levels were comparable between malnourished and well-nourished subjects in most prior studies, 165 
reduced seroconversion rates or antibody titers were reported after typhoid, diphtheria, tetanus, 166 
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hepatitis B, measles and other vaccinations in severe malnutrition, though this does not appear to be as 167 
uniform a finding for moderate and mild malnutrition [64]. While these deficits likely impair an efficient 168 
response to pathogens, it is important to note the changes appear reversible and nutritional 169 
rehabilitation of malnourished individuals is associated with an improvement in adaptive lymphocyte 170 
proliferative responses, chemotaxis, and cytokine production [69]. 171 
 172 
Part 2: Adipose Tissue and Immune Activation in Comorbid HIV and Obesity 173 
Adipose tissue represents one of the largest organs in the body and comprises a range of cell types with 174 
diverse energy storage, metabolic regulation, neuroendocrine, and immunologic functions. HIV infection 175 
and ART treatment cause alterations to adipose tissue distribution and biology with broad effects on 176 
cytokine and hormone expression, lipid storage, and the composition of adipose-resident immune cell 177 
populations. The resultant changes have important consequences for innate and adaptive immune 178 
responses and chronic immune activation. 179 
 180 
Obesity prevalence in the HIV population 181 
The proportion of overweight and obese individuals in high- and middle-income countries has increased 182 
steadily over the past three decades, affecting all race/ethnicity, sex, and age groups to varying degrees, 183 
and more recently obesity rates have increased in low-income countries [70]. More than one-third of 184 
adults in the United States are overweight (BMI 25-29.9 kg/m2) and a similar proportion are obese (BMI 185 
>30 kg/m2) [71]. Obesity is also becoming more prevalent in the HIV population. In an analysis of over 186 
14,000 HIV-infected persons in the United States and Canada, the percentage of patients who were 187 
obese at ART initiation increased from 9% to 18% between 1998 and 2010, and 22% of individuals with 188 
normal BMI (18.5-25 kg/m2) at treatment initiation had become overweight after three years of ART, 189 
and 18% of those overweight at initiation had become obese. Compared to age-matched National 190 
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Health-Nutrition Examination Survey (NHANES) controls from the general population, HIV-infected 191 
white women had a higher BMI after 3 years of ART as compared to controls, while no difference in BMI 192 
after 3 years of ART was observed for HIV-infected white men and non-white men and women 193 
compared to controls [2].  194 
 195 
HIV infection alters adipose tissue distribution and metabolic characteristics 196 
Older ART agents, particularly the thymidine analogues zidovudine (AZT) and stavudine (d4T), were 197 
associated with a high prevalence (up to 50% in some studies) of peripheral lipoatrophy of the limbs, 198 
face, and buttocks; lipohypertrophy of the visceral, cervical, and dorsocervical area (i.e., the “buffalo 199 
hump”); or a combination of these changes [72, 73]. The accumulation of ectopic adipose tissue in a 200 
variety of organs, particularly epicardial, hepatic, and muscle bundle fat infiltration, contributes to local 201 
inflammation and end-organ disease [74-76]. Subcutaneous fat biopsies from individuals with HIV-202 
associated lipoatrophy demonstrate reduced mitochondrial DNA (mtDNA) and structural changes 203 
characterized by increased fibrosis, apoptosis, and formulation of lipogranulomas, while the adipocytes 204 
demonstrate reduced expression of several transcription factors necessary for cellular differentiation 205 
and fatty acid uptake, but higher TNF-α and IL-6 expression [77-81]. Taken together, these findings 206 
indicate a shift to a pro-inflammatory, profibrotic, and dysregulated metabolic state within the fat tissue 207 
of HIV patients. While the prevalence of lipodystropy has declined with the introduction of newer ART 208 
agents, the presence of HIV viral particles and latently HIV-infected, adipose-resident CD4+ T cells within 209 
adipose tissue may still contribute to impaired lipid metabolism and storage [82, 83].  210 
 211 
Obesity, HIV, and the microbiome 212 
As discussed above in the sections on malnutrition, HIV-infection can be accompanied by a marked 213 
dysbiosis of fecal and mucosal-adherent bacteria characterized by increased Proteobacteria and reduced 214 
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Bacteroidetes and Firmicutes, and these changes are associated with mucosal T cell activation, 215 
circulating T cell activation, and serum markers of innate immune activation [44, 45]. Independent of 216 
HIV infection, obesity is accompanied by characteristic changes in the gastrointestinal microbiome 217 
characterized by lower levels of Bacteroidetes and proportionately higher levels of Firmicutes in several 218 
studies [84-86], which are postulated to enhance dietary nutrient absorption [87]. In animal models, 219 
stool characterized by this phylum-level shift was shown to ‘transmit’ obesity when inoculated into lean 220 
animals [84], suggesting that alterations of the gastrointestinal microbiome by conditions such as HIV 221 
infection could alter energy uptake and the metabolic balance. Colon biopsies of untreated, HIV-infected 222 
persons show reduced Firmicutes but little change in Bacteroidetes at the phylum level compared to 223 
HIV-negative controls (however, the relative composition of Bacteroidetes at the genus level did shift) 224 
[45]. Based on prior animal and human studies, this alteration in the Bacteroidetes : Firmicutes ratio in 225 
untreated HIV would appear to be protective against obesity. However, many patients gain weight after 226 
ART initiation, particularly in the first 12 months, and the potential contribution of microbiome changes 227 
after ART initiation to weight gain is one area for further study [2]. 228 
 229 
Obesity is associated with increased serum inflammatory markers in HIV-infected persons 230 
As observed in the general population, serum levels of CRP are higher among HIV-infected adults with 231 
greater adiposity [88-91]. In the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) 232 
cohort, each twofold increase in visceral adipose tissue was associated with 17% higher serum CRP, 233 
while a similar increase in subcutaneous adipose tissue was associated with 21% higher levels [88]. 234 
Circulating levels of IL-6, TNF-α receptor 1, and macrophage inflammatory protein-1α also rise in 235 
proportion to fat mass in HIV-infected persons, likely due to greater expression from stromal vascular 236 
cells and hypertrophied adipocytes [91, 92]. The enlargement of adipose tissue depots is primarily due 237 
to adipocyte hypertrophy, rather than hyperplasia, and increases in adipocyte size result in 238 
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disproportionate increases in IL-6 and TNF-α expression [93-95]. It is estimated that adipose tissue-239 
derived IL-6  constitutes up to 35% of circulating levels in obese individuals and is a substantial 240 
contributor to CRP production [96]. This raises the question of whether the reported association 241 
between CRP or IL-6 levels and adverse health outcomes in studies of predominantly non-obese 242 
populations should be extrapolated to obese HIV-infected individuals, as in the obese a higher 243 
proportion of these biomarkers may emanate from adipose tissue as opposed to other sites of 244 
inflammation [97-99]. 245 
 246 
Obesity and adipose tissue immune cell profiles 247 
Immune cell infiltration of adipose tissue accompanies progressive weight gain and contributes to both 248 
in situ and systemic inflammation. Adipose tissue from obese humans and animal models shows a 249 
striking increase in CD8+ T cells and TH1 and TH17-polarized CD4+ cells, a decrease in T regulatory cells, 250 
and an increase in M1-phenotype (TNF-α, IL-12, IL-23-producing) pro-inflammatory macrophages [100-251 
103]. CD8+ T cell infiltration into adipose tissue is an early and necessary step preceding M1-phenotype 252 
macrophage recruitment in mice, and antibody-induced CD8+ T cell depletion results in reduced M1-253 
phenotype macrophage adipose tissue infiltration [100].  Adipocyte hypertrophy is associated with 254 
increased production of macrophage chemotactic protein-1 and macrophage inflammatory protein-1α, 255 
which promote macrophage infiltration, and increased IL-8, which promotes neutrophil chemotaxis 256 
[104-106].  257 
 258 
Recent studies highlight an important role for TH17 cells, a subset of CD4+ effector T cells defined by 259 
their production of IL-17, in promoting adipose tissue inflammation and metabolic disease [107, 108]. 260 
TH17 cells are central contributors to the maintenance of mucosal barriers, pathogen clearance at the 261 
mucosal surface, and the defense against fungi and extracellular bacteria [109, 110], but loss or 262 
15 
 
dysregulation of TH17 cells is also implicated in the pathogenesis of autoimmune and inflammatory 263 
conditions [111]. Adipose tissue CD4+ T cells in obese, insulin resistant persons are skewed toward a 264 
TH17 phenotype, and the tissue microenvironment is characterized by high levels of TH17-promoting IL-265 
1β and IL-6 in addition to the TH17 markers RORC, IL-17, and IL-23R [107, 112]. M1-phenotype 266 
macrophage cytokine expression promotes a cycle of progressive TH17-polarization and inflammation, 267 
with IL-1β and IL-6 promoting the differentiation of TH17 cells and IL-23 promoting their stabilization and 268 
expansion [113, 114]. While circulating IL-17 levels are frequently low or undetectable, in vitro IL-17 269 
inhibits skeletal muscle glucose uptake and hepatocyte insulin sensitivity [107]. A recent study describes 270 
the role of ATP leakage into the extracellular space, a hallmark of pathologic cellular conditions such as 271 
apoptosis, inflammation, or ischemia, in promoting a TH17-polarizing milieu [115]. The addition of ATP to 272 
visceral adipose tissue from metabolically healthy lean subjects enriched the tissue microenvironment 273 
for IL-1β, IL-6, and IL-17, and higher CD4+ T cell expression of a characteristic TH17 cytokine signature 274 
[112]. These studies suggest a central role for TH17 CD4+ cells in propagating adipose tissue 275 
inflammation, and further studies are needed to understand whether HIV status alters the distribution 276 
and activity of adipose tissue TH17-polarized cells in obesity. 277 
 278 
Adipose tissue also serves as a reservoir of CD4+ T cells harboring latent HIV infection. A recent study 279 
found a higher percentage of activated CD4+ and CD8+ T cells in adipose tissue from HIV-infected 280 
subjects compared to HIV-negative controls, in addition to the unique presence of latently HIV-infected 281 
memory CD4+ T cells [82, 116]. Furthermore, the median copy number of latent HIV DNA in 282 
subcutaneous adipose tissue CD4+ T cells was slightly higher than the median copy number in circulating 283 
CD4+ T cells, indicating adipose tissue serves as a significant reservoir for latent HIV infection [116]. 284 
Similar findings regarding a higher proportion of activated CD8+ and CD4+ T cells, and latently infected 285 
16 
 
memory CD4+ T cells, in both subcutaneous and visceral adipose tissue have been reported in simian 286 
immunodeficiency virus-infected macaques compared to uninfected animals [116].  287 
 288 
Obesity and circulating T cell profiles in HIV-infected and HIV-negative persons 289 
Studies from the pre-ART era found a higher BMI was associated with slower disease progression and 290 
CD4+ T cell decline [117-119]. However, it is unclear whether the delayed immunosuppression observed 291 
among high BMI individuals was due to an effect of greater adiposity versus other factors such as fewer 292 
secondary infections or micronutrient deficiencies. Recent studies in the combination ART era found a 293 
higher BMI may promote more robust CD4+ T cell recovery on treatment [120, 121]. An analysis of over 294 
14,000 HIV-infected adults in 13 multi-site cohorts found a higher time-updated BMI was significantly 295 
associated with greater CD4+ cell count recovery on ART [122]. After 5 years of ART, the mean CD4+ cell 296 
count for a hypothetical patient with a BMI of 30 kg/m2 was 20% higher compared to a patient with a 297 
BMI of 22 kg/m2 (524 vs. 436 cells/µL),  and 31% higher for a BMI of 40 kg/m2 compared to 22 kg/m2 298 
(572 vs. 436 cells/µL). 299 
 300 
A minimum quantity of adipose tissue appears necessary to maintain normal-range lymphocyte subset 301 
counts, but assessing the relationship between adiposity and peripheral T cell populations in the setting 302 
of HIV infection is confounded by CD4+ T cell depletion, variations in immune recovery on ART, and the 303 
effects of HIV-related immune activation.  Thus, studies of HIV-negative individuals may be revealing in 304 
this area. Overweight and obese HIV-negative women had higher CD4+ and total lymphocyte counts 305 
compared to normal weight women in one study [123], while the expression of activation marker CD25 306 
on CD3+ T cells was 3-fold higher in obese subjects compared to non-obese, and the ratio of TH1 to TH2 307 
CD4+ lymphocytes was also significantly higher, in another study [124]. Similarly, an analysis of the 308 
European CODAM cohort of HIV-negative individuals found greater waist circumference was associated 309 
17 
 
with higher circulating markers of adaptive immune activation (neopterin and soluble CD25) [125]. 310 
Taken together, these data suggest that, irrespective of HIV infection, higher fat stores are associated 311 
with higher circulating CD4 T cell populations, greater TH1 polarization, and expression of surface 312 
markers of immune activation. 313 
 314 
Adipose tissue hormones alter lymphocyte function  315 
Adipokines are hormones produced by adipocytes which demonstrate a range of metabolic, 316 
neuroendocrine, and immunomodulatory properties.  Leptin, an adipokine encoded by the ob gene and 317 
produced roughly in proportion to fat cell mass, was initially characterized as a regulator of appetite but 318 
also appears to have a range of local and potentially systemic immune effects [126-128]. Leptin 319 
independently induces expression of pro-inflammatory cytokines by macrophages and monocytes [129, 320 
130], and acts directly on hepatocytes to promote CRP expression [131]. Mature CD4+ T cells express 321 
the long isoform of the leptin receptor [132, 133], and leptin stimulates T cell proliferative responses in 322 
vitro, polarizes naïve CD4+ T cell proliferation towards the TH1 phenotype, and promotes a marked 323 
increase in IFN-γ and other TH1-type cytokines [133-137]. Leptin also enhances in vitro expression of 324 
activation markers (CD69, CD25, and CD71) on both CD4+ and CD8+ T cells after antigen stimulation in a 325 
dose-dependent manner [136, 138]. While the administration of physiologic quantities of recombinant 326 
leptin to non-HIV-infected adults with acquired or congenital lipodystrophy increased peripheral CD4+ 327 
and CD8+ cell counts, two small trials in HIV-infected individuals have not shown a benefit to CD4+ cell 328 
recovery on ART [139-142].  329 
 330 
Therapeutic trials to reduce adiposity and immune activation in HIV-infected individuals 331 
Trials of exercise and lifestyle modification have shown reductions in serum CRP, weight loss, and 332 
improved cardiorespiratory fitness in HIV persons, though benefits for insulin sensitivity and fasting 333 
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glucose are less clear [143-146]. In morbidly obese HIV-infected persons, bariatric surgery appears to be 334 
safe and does not affect viral suppression [147, 148].  335 
 336 
The accumulation of visceral fat in HIV-infected individuals is accompanied by reductions in endogenous 337 
circulating and stimulated growth hormone (GH) levels, a finding also observed in HIV-negative persons 338 
with abdominal obesity and independent of age, BMI, and total body fat [149-151]. Inadequate GH 339 
levels are associated with reduced bone mineralization, dyslipidemia (characterized by elevated 340 
triglycerides and low HDL), elevated blood pressure, reduced vascular health, higher circulating CRP, and 341 
a detrimental cycle of further accumulation of visceral adiposity with concomitant progressive 342 
reductions in GH secretion [152-155]. Among HIV-infected persons, lower peak levels of GH are 343 
associated with higher CRP levels, in addition to higher fasting glucose levels and triglycerides 344 
independent of waist circumference [156].  345 
 346 
Studies of GH replacement in persons with hypopituitarism demonstrated reductions in visceral 347 
adiposity and inflammation, and improved lipid parameters and markers of vascular health, which 348 
suggested possible benefits for HIV-infected persons with abdominal obesity [153, 157-159]. However, 349 
while trials of recombinant human growth hormone (rhGH) in obese, HIV-infected persons have shown 350 
reductions in visceral adipose tissue and hepatic fat [160-162], these benefits must be weighed against 351 
the increased insulin resistance observed with rhGH treatment [161-164]. Furthermore, the beneficial 352 
effects of GH supplementation on innate immune activation in persons with hypopituitarism are not as 353 
evident in HIV-infected individuals. A multi-arm study of rhGH, rosiglitazone, combination rhGH and 354 
rosiglitazone, and placebo found no significant difference in a range of serum inflammation biomarkers, 355 
including CRP, IL-1, IL-6, TNF-α, and interferon gamma, between study arms after 12 weeks of treatment 356 
[160].  357 
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 358 
Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), is a FDA-approved 359 
treatment to reduce abdominal fat in HIV-infected patients with lipodystrophy. Trials of Tesamorelin 360 
demonstrate visceral and hepatic fat reductions, gains in lean body mass, and improved lipid profiles, 361 
but without the increase in insulin resistance which limited the clinical utility of rhGH [165-167]. 362 
However, despite substantial reductions in visceral fat with Tesamorelin, it is notable that a 26-week 363 
randomized trial did not demonstrate a significant effect on CRP levels, and more studies are needed to 364 
characterize the effects of Tesamorelin on innate and cellular immune activation [168].  365 
 366 
Conclusion 367 
Persistent, chronic innate and adaptive immune activation have been implicated in the pathogenesis of 368 
multiple comorbidities in HIV patients and impaired immune recovery on ART. While the etiology of this 369 
heightened immune activation is multifactorial, the immunologic effects of HIV infection can be 370 
amplified and modulated by host nutritional factors. At the intersection of these nutritional and 371 
immunologic processes an opportunity may be present for interventions to mitigate the adverse effects 372 
of both malnutrition and obesity on chronic immune activation and improve health outcomes in HIV-373 
infected individuals. 374 
20 
 
 References 
 375 
1. Hasse B, Iff M, Ledergerber B, et al. Obesity Trends and Body Mass Index Changes After Starting 376 
Antiretroviral Treatment: The Swiss HIV Cohort Study. Open Forum Infect Dis 2014; 1:ofu040. 377 
2. Koethe JR, Jenkins CA, Lau B, et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting 378 
Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50-8. 379 
3. Koethe JR, Heimburger DC. Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. Am J 380 
Clin Nutr 2010; 91:1138S-1142S. 381 
4. Kotler DP, Tierney AR, Wang J, Pierson RN, Jr. Magnitude of body-cell-mass depletion and the timing 382 
of death from wasting in AIDS. Am J Clin Nutr 1989; 50:444-7. 383 
5. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency 384 
virus infection. N Engl J Med 1995; 333:83-8. 385 
6. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, 386 
caloric intake, and short-term weight change in human immunodeficiency virus infection and the 387 
acquired immunodeficiency syndrome. Am J Clin Nutr 1992; 55:455-60. 388 
7. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy 389 
expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999; 390 
13:1351-7. 391 
8. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-392 
infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr 393 
1993; 57:614-9. 394 
9. Yarasheski KE, Zachwieja JJ, Gischler J, Crowley J, Horgan MM, Powderly WG. Increased plasma gln 395 
and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol 1998; 396 
275:E577-83. 397 
10. Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body protein turnover 398 
from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J 399 
Clin Nutr 1995; 61:818-26. 400 
11. Food and Agricultural Organzation of the United Nations. The State of Food Insecurity in the World 401 
2014. Rome: FAO, 2014. Available at: http://www.fao.org/publications/sofi/2014/en/. 402 
12. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among 403 
malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 404 
2010; 53:507-13. 405 
21 
 
13. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in 406 
HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-407 
33. 408 
14. Canipe A, Chidumayo T, Blevins M, et al. A 12 week longitudinal study of microbial translocation and 409 
systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy. BMC 410 
Infect Dis 2014; 14:521. 411 
15. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune 412 
activation in chronic HIV infection. Nat Med 2006; 12:1365-71. 413 
16. Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. Am 414 
J Trop Med Hyg 2012; 86:756-63. 415 
17. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of 416 
HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011; 25:1385-1394. 417 
18. Leon A, Leal L, Torres B, et al. Association of microbial translocation biomarkers with clinical 418 
outcome in controllers HIV-infected patients. AIDS 2015; 29:675-81. 419 
19. Sandler NG, Wand H, Roque A, et al. Plasma Levels of Soluble CD14 Independently Predict Mortality 420 
in HIV Infection. J Infect Dis 2011; 203:780-790. 421 
20. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Pre -cART Pro -inflammatory milieu, Microbial 422 
Translocation (MT) and Risk of  Disease Progression in HIV-infected Patients Starting Their First cART: 423 
Data from the Icona Foundation Cohort. In: European AIDS Clinical Society (EACS), Barcelona; 2015.  424 
2015. 425 
21. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure 426 
in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. 427 
AIDS 2008; 22:2035-8. 428 
22. Elia M, Goren A, Behrens R, Barber RW, Neale G. Effect of total starvation and very low calorie diets 429 
on intestinal permeability in man. Clin Sci (Lond) 1987; 73:205-10. 430 
23. Welsh FK, Farmery SM, MacLennan K, et al. Gut barrier function in malnourished patients. Gut 1998; 431 
42:396-401. 432 
24. Kelly P, Menzies I, Crane R, et al. Responses of small intestinal architecture and function over time to 433 
environmental factors in a tropical population. Am J Trop Med Hyg 2004; 70:412-9. 434 
25. Veitch AM, Kelly P, Zulu IS, Segal I, Farthing MJ. Tropical enteropathy: a T-cell-mediated crypt 435 
hyperplastic enteropathy. Eur J Gastroenterol Hepatol 2001; 13:1175-81. 436 
26. Dhaliwal W, Bajaj-Elliott M, Kelly P. Intestinal defensin gene expression in human populations. Mol 437 
Immunol 2003; 40:469-75. 438 
22 
 
27. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and 439 
nonpathogenic lentiviral infections. Blood 2008; 112:2826-35. 440 
28. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial 441 
barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852. 442 
29. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in 443 
primary human immunodeficiency virus infection is driven by an imbalance between immune response 444 
and mucosal repair and regeneration. J Virol 2008; 82:538-45. 445 
30. Keating J, Bjarnason I, Somasundaram S, et al. Intestinal absorptive capacity, intestinal permeability 446 
and jejunal histology in HIV and their relation to diarrhoea. Gut 1995; 37:623-9. 447 
31. Kapembwa MS, Fleming SC, Sewankambo N, et al. Altered small-intestinal permeability associated 448 
with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin Sci 449 
(Lond) 1991; 81:327-34. 450 
32. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in 451 
primary HIV infection predict the T-cell activation set point in the absence of systemic microbial 452 
translocation. PLoS Pathog 2013; 9:e1003453. 453 
33. Smith AJ, Schacker TW, Reilly CS, Haase AT. A role for syndecan-1 and claudin-2 in microbial 454 
translocation during HIV-1 infection. J Acquir Immune Defic Syndr 2010; 55:306-15. 455 
34. Jenabian MA, El-Far M, Vyboh K, et al. Immunosuppressive Tryptophan Catabolism and Gut Mucosal 456 
Dysfunction Following Early HIV Infection. J Infect Dis 2015; 212:355-66. 457 
35. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31:107-33. 458 
36. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human 459 
intestine. Science 2005; 307:1915-20. 460 
37. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune 461 
system. Science 2012; 336:1268-73. 462 
38. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev 463 
Microbiol 2016; 14:20-32. 464 
39. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role 465 
for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin 466 
Microbiol 2008; 46:757-8. 467 
40. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected 468 
subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with 469 
immune activation. J Acquir Immune Defic Syndr 2011; 57:363-70. 470 
23 
 
41. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic 471 
flora translocating in peripheral blood of HIV-infected patients with poor immune response to 472 
antiretroviral therapy. PLoS One 2011; 6:e18580. 473 
42. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal 474 
microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 475 
10:e1003829. 476 
43. Voigt RM, Keshavarzian A, Losurdo J, et al. HIV-associated mucosal gene expression: region-specific 477 
alterations. AIDS 2015; 29:537-46. 478 
44. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV 479 
disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91. 480 
45. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is 481 
associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014; 482 
7:983-94. 483 
46. Perez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4 484 
and less microbial translocation during HIV infection. AIDS 2013; 27:1921-31. 485 
47. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic 486 
inflammation in chronic HIV infection. J Infect Dis 2015; 211:19-27. 487 
48. Smythe PM. Changes in intestinal bacterial flora and role of infection in Kwashiorkor. Lancet 1978; 488 
2:724-727. 489 
49. Monira S, Nakamura S, Gotoh K, et al. Gut microbiota of healthy and malnourished children in 490 
bangladesh. Front Microbiol 2011; 2:228. 491 
50. Ghosh TS, Gupta SS, Bhattacharya T, et al. Gut microbiomes of Indian children of varying nutritional 492 
status. PLoS One 2014; 9:e95547. 493 
24 
 
Table: Summary Points on Nutrition and Immune Activation 
 Enteropathy due to a confluence of environmental factors, nutrition deficits, and viral effects impairs mucosal barrier integrity 
and immune defenses, and contributes to both innate and cellular immune activation in malnourished HIV-infected persons. 
 A gastrointestinal dysbiosis, characterized by increased Proteobacteria and reduced or altered Bacteroidetes and Firmicutes, is 
present in HIV patients, and these changes are accompanied by increased mucosal and circulating T cell activation and systemic 
inflammation. Similar phylum-level changes occur in malnutrition, but the microbiome consequences of comorbid HIV infection 
and malnutrition are unknown. 
 Malnutrition is associated with reduced T cell proliferative responses, reduced T cell expression of activation and memory 
surface markers, greater type-2 T helper cell (TH2) polarization, and decreased TH1 cell interferon-γ and interleukin-2 production, 
which compound HIV-related immunodeficiency and impair clearance or control of secondary infections. 
 Adipocytes constitutively express interleukin-6, tumor necrosis factor-α, and other cytokines, and obese HIV-infected persons 
have substantially higher circulating levels of inflammation biomarkers. Because these cytokines derive from adipocytes as 
opposed to other tissues (e.g., blood vessels), obesity may confound previously reported associations between inflammation 
and health outcomes in HIV-infected persons. 
 A higher BMI is associated with more robust CD4+ recovery on antiretroviral therapy, and obesity in is associated with higher 
circulating T cell counts, increased T cell activation, and CD4+ cell TH1 polarization in studies of HIV-negative individuals. 
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 CD4+ T cells express a receptor for leptin, an adipokine produced by adipocytes, which may have an endocrine function 
modulating T cell proliferation, activation, and T-helper cell polarization in states of both malnutrition and obesity.  
 Clinical trials of growth-hormone-releasing hormone (GHRH) have shown a beneficial effect for reducing visceral and hepatic fat 
without the added insulin resistance observed in studies of recombinant growth hormone. However, the effect of GHRH on 
innate and cellular immune activation is still unclear.  
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